Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meningococcal serogroup C conjugate booster response in older children previously vaccinated in infancy and second year of life
2005-001638-34Phase 4Terminated
- Sponsor
- Health Protection Agency
- Start
- Aug 2005
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of meningococcal group c polysaccharide-tetanus toxoid conjugate vaccine in meningococcal disease, sponsored by Health Protection Agency. Primary endpoints: Serum bactericidal antibody (SBA) response: mean fold rise, Serum bactericidal antibody (SBA) response: proportion with 4-fold rise and 2 more. Started Aug 2005; status: terminated.
02
Drugs
meningococcal group c polysaccharide-tetanus toxoid conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2005-001638-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001638-34.